EUCTR2008-002606-18-GB进行中（未招募）不适用
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid Tumours
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of signed written informed consent
- •2. Male or female, aged 18 years or older
- •3. Cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study. Inclusion is irrespective of stage of disease.
- •4. Histological or cytological confirmation of an advanced, solid, malignant tumour (or lymphoma, Part A only).
- •5. WHO performance status 0-2 (those with performance status 2 must have been stable with no deterioration over the previous 2 weeks)
- •6. Evidence of post-menopausal status, permanent or surgically sterile, or negative serum or urine pregnancy test for female patients of child-bearing potential. Women will be considered post menopausal if they are over 50 years old and have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments. Permanent sterilisation includes hysterectomy and/or bilateral oopherectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion. Tubal occlusion is considered a highly effective method of birth control but does not absolutely exclude the possibility of pregnancy. (The term occlusion refers to both occluding and ligating techniques that do not physically remove the oviducts). Women who have undergone tubal occlusion should be managed as if they are of child-bearing potential (eg undergo pregnancy testing as required by the study). Females of reproductive potential are required to use reliable contraception (see Section 3.3.4)
- •7. For Part A of the study, patients with measurable and non-measurable disease (according to RECIST criteria) can be recruited.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Laboratory values as listed below: (SI Units)
- •- ANC <1.5x109/L
- •- Platelets <100x109/L
- •- Haemoglobin (Hb) <9.0 g/dL
- •- AST (SGOT) or ALT (SGPT) >2.5 x ULN if no demonstrable liver metastases or >5 x ULN in the presence of liver metastases, total bilirubin (TBL) >1.5 x ULN if no demonstrable liver metastases or >3 x ULN in the presence of liver metastases
- •- Serum creatinine >1.5 x ULN or creatinine clearance =50 mL/min (measured or calculated by Cockcroft-Gault method)
- •- Clinically relevant and treatment resistant abnormalities in potassium, sodium, calcium (corrected for plasma albumin) or magnesium
- •2. Endometrial cancer who have isolated recurrences of their disease (vaginal, pelvic or para-aortic) that are amenable to potentially curative treatment with radiation therapy or surgery
- •3. Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, corticosteroids or other investigational anti-cancer therapy within 21 days of entering the trial (not including palliative radiotherapy at focal sites). Patients must have also recovered from previous chemo-associated toxicities to Grade 0-1 (with the exception of alopecia).
- •4. Treatment with any haemopoietic growth factors (eg G-CSF, GM-CSF) within 2 weeks prior to receiving study drug
- •5. Active spinal cord compression as evidenced by clinical signs and/or oedema or progressive growth demonstrated by imaging unless treated and stable off steroids for at least 1 month prior to study treatment
- •6. Peripheral neuropathy CTCAE grade > 1 in the past 4 weeks. History of pre-existing leg weakness or muscle diseases
- •7. Family history of myopathy
- •8. Past history or current evidence of brain metastases
- •9. Evidence of severe or uncontrolled systemic conditions (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol 10. Patients with pre existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or Renal tubular acidosis
- •11. Abnormal fasting glucose value defined as >126 mg/dL (> 7 mmol/L).
- •12. Manifest Diabetes Type I and II or Erythrocyte-HbA1c >6.5%
- •13. Uncontrolled hypercholesterolaemia or hypertriglyceridaemia (fasting state) despite lipid-lowering therapy
- •14. Evidence of active infection or active bleeding diatheses
- •15. Experience of any of the following in the preceding 12 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction (MI), angina pectoris, congestive heart failure NYHA Grade 2, uncontrolled hypertension (BP>150/90 mmHg despite maximal medical management), ventricular arrhythmias requiring continuous therapy, supraventricular arrhythmias including AF, which are uncontrolled, haemorrhagic or thrombotic stroke, including transient ischaemic attacks or any other central nervous system bleeding
- •16. Abnormal echocardiogram at baseline (LVEF < 55% and shortening fraction SF <15%)
- •17. Torsades de Pointes, currently or within 2 weeks of study entry
- •18. Patients with mean QTc interval >450ms from 3 ECGs using Fridericia's correction at both screening visit and predose on the first day of dosing
- •19. Patients taking concomitant medications known to prolong QT interval or with factors that increase the risk of QT prolongation or arrhythmic events (heart failure, hyperka
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid Tumours, Lymphomas and Endometrial CarcinomaEUCTR2008-002606-18-FRAstrazeneca AB100
进行中（未招募）
1 期
To investigate the safety and tolerability of AZD9291 when given orally to patients with non small cell lung cancer. These patients will be chosen from those who have already been prescribed an EGFR TKI medicine (such as Iressa or Tarceva).on-Small Cell Lung CancerMedDRA version: 16.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004628-39-ITAstraZeneca AB375
进行中（未招募）
1 期
Glioma treated with AZD4547Recurrent grade III or IV glioma with FGFR3-TACC3 or FGFR1-TACC1 fusion positive by RT-PCRMedDRA version: 18.1 Level: PT Classification code 10018336 Term: Glioblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005428-81-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)38
进行中（未招募）
1 期
To investigate the safety and tolerability of AZD9291 when given orally to patients with non small cell lung cancer. These patients will be chosen from those who have already been prescribed an EGFR TKI medicine (such as Iressa or Tarceva).EUCTR2012-004628-39-GBAstraZeneca AB375
进行中（未招募）
1 期
To investigate the safety and tolerability of AZD9291 when given orally to patients with non small cell lung cancer. These patients will be chosen from those who have already been prescribed an EGFR TKI medicine (such as Iressaor Tarceva).on-Small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004628-39-DEAstraZeneca AB375